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Members of the Bcl-2 family are major regulators of apoptosis in mammalian cells, and 
hence infection-induced perturbations in their expression could result into elimination 
of the parasites or creation of a niche favoring survival. In this investigation, we uncover 
a novel role of host Bcl-2 in sustaining Leishmania donovani infection. A rapid twofold 
increase in Bcl-2 expression occurred in response to parasite challenge. Downregulation 
of post infection Bcl-2 increase using siRNA or functional inhibition using Bcl-2 small 
molecule inhibitors interfered with intracellular parasite survival confirming the necessity 
of elevated Bcl-2 during infection. An increased nitric oxide (NO) response and reduced 
parasitic burden was observed upon Bcl-2 inhibition, where restitution of the NO 
response accounted for parasite mortality. Mechanistic insights revealed a major role 
of elevated Th2 cytokine IL-13 in parasite-induced Bcl-2 expression via the transcription 
factor STAT-3, where blocking at the level of IL-13 receptor or downstream kinase JAK-2 
dampened Bcl-2 induction. Increase in Bcl-2 was orchestrated through Toll like receptor 
(TLR)-2-MEK-ERK signaling, and changes in TLR-2 levels affected parasite uptake. In a 
mouse model of visceral leishmaniasis (VL), Bcl-2 inhibitors partially restored the antimi-
crobial NO response by at least a twofold increase that resulted in significantly reduced 
parasite burden. Interestingly, monocytes derived from the peripheral blood of six out 
of nine human VL subjects demonstrated Bcl-2 expression at significantly higher levels, 
and sera from these patients showed only marginally quantifiable nitrites. Collectively, 
our study for the first time reveals a pro-parasitic role of host Bcl-2 and the capacity of 
host-derived IL-13 to modulate NO levels during infection via Bcl-2. Here, we propose 
Bcl-2 inhibition as a possible therapeutic intervention for VL.
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inTrODUcTiOn
Pathogens manipulate host-cell proteins to survive, and the ones supporting their persistence form 
attractive targets for development of drugs. Apoptosis is a cellular process, frequently encountered to 
be manipulated during infection (1). During the course of a pathogenic invasion, host-cell apoptosis 
serves as an innate immune mechanism by warding off the multiplication and the spread of the 
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pathogen at the cost of the infected cell (2, 3). The pathogen on 
the other hand antagonizes this defense by manipulating host-cell 
proteins regulating this very process (1, 4). The Bcl-2 family of pro 
and antiapoptotic regulatory proteins expressing Bcl-2 homology 
or BH domains primarily controls the well-orchestrated process 
of apoptosis within mammalian cells along with other related 
functions (5). These proteins are druggable targets because of their 
involvement in vital cellular functions. Interestingly, this family 
also represents one such class of molecules that is modulated dur-
ing bacterial and viral infections (1, 6, 7), however, their role in 
protozoal infection is not known. Bcl-2 family proteins expressing 
four BH domains are antiapoptotic, like Bcl-2, Mcl-1, and Bcl-xL, 
and pro-apoptotic proteins like Bad and Bik express three or one 
BH domains respectively (8). The different members of the family 
form homo or heterodimers through the BH3 domain to regulate 
various cellular functions including autophagy and apoptosis. 
Understanding of this binding has led to the development of BH3 
mimetics capable of interfering with functions of proteins like 
Bcl-2, Bcl-xL, and Mcl-1. ABT-263 is a small molecule inhibitor 
for Bcl-2, Bcl-xL, and Bcl-w while ABT-199 is a specific inhibitor 
for Bcl-2, which is in clinical trials for cancer treatment (9, 10). 
While ABT-263 is still in phase-II trials, ABT-199, created by 
re-engineering of ABT-263 to make it more Bcl-2-specific, has 
been given the “Breakthrough Therapy Designation” by the FDA 
in 2015 for the treatment of lymphoid malignancies.
The involvement of the Bcl-2 family of proteins in prevent-
ing or inducing host-cell death has been explored for bacterial 
pathogens like Mycobacterium tuberculosis where infection 
upregulates Bcl-2 in mouse macrophages and THP-1 cells 
through the mitogen-activated protein kinase (MAPK) pathway 
(11). Another bacterial pathogen M. leprae, downregulates pro-
apoptotic Bcl-2 family members Bad and Bak and upregulates the 
antiapoptotic Mcl-1 protein to prevent host-cell apoptosis (12). 
However, in all the above studies, functional involvement of Bcl-2 
is not well elucidated.
While the mechanisms of Leishmania infection have been 
widely explored, there is no information on how host Bcl-2 
behaves during infection with this parasitic protozoan. For 
elimination of the Leishmania parasite, the microbicidal molecule 
nitric oxide (NO) produced by the activity of the inducible nitric 
oxide synthase (iNOS) enzyme is crucial (13, 14). Deficient or 
impaired NO response leads to resistance to antimonial drugs, 
the main line of therapy against visceral leishmaniasis (VL) (15). 
The sensitivity of the Leishmania parasite to NO suggests that 
boosting of mechanisms that allow NO to be generated in infected 
cells would be an effective means of eliminating infection. Bcl-2 is 
known to suppress NO production in mammalian cells (16) but it 
is not known if Bcl-2 influences NO production in macrophages 
during L. donovani infection.
The idea that Bcl-2 family proteins play a role in pathogen 
survival prompted us to check if they were also important for 
the success of L. donovani infection and if interference with these 
proteins could abridge parasitic burden. Using both in vitro and 
in vivo experimental systems, we, demonstrate increased expres-
sion of the Bcl-2 protein in response to L. donovani infection 
and also show that suppression or functional inhibition of the 
infection-induced Bcl-2 results in accelerated clearance of the 
parasites. Our results assign a pro-parasitic role to the cytokine 
IL-13 by showing its involvement in the suppression of NO pro-
duction via Bcl-2 induction. We also present evidence in support 
of the involvement of the host surface toll-like receptor (TLR)-2 
in Bcl-2 induction and in the early interaction and subsequent 
internalization of the parasites by the macrophages. The data 
demonstrates a new possibility of use of Bcl-2 small molecule 
inhibitors as antileishmanial agents.
MaTerials anD MeThODs
ethics statement
All animal experiments were duly approved by the Institutional 
Animal Ethics Committee of the National Institute of Immunology, 
New Delhi (IAEC/AQ/2015/134, serial no. IAEC#372/15). Use 
of human peripheral blood monocytes (PBMCs) was approved 
by the Institutional Human Ethics Committee of the National 
Institute of Immunology, New Delhi (Project no. IHEC #84/14). 
The work involving human subjects was also approved by the 
ethical committee of the Institute of Medical Science, Banaras 
Hindu University, Varanasi, India, and the informed consents 
were obtained from the patients or their guardians.
study subjects
Subjects with symptoms of VL were recruited to Kala-Azar 
Medical Research Centre, Muzaffarpur, Bihar, India, where they 
were confirmed to be positive for VL by detection of amastigotes 
in the splenic aspirates and/or by rK39 positive test. All patients 
included in the study were HIV negative and over 6 years of age. 
Splenic aspiration is the gold standard method for diagnosis of VL; 
splenic aspirates were collected before the start of antileishmanial 
treatment and after cure for examining parasitological status of 
subjects. Subjects with low hemoglobin, platelet count less than 
40,000/μl and prothrombin time <5  s were excluded from the 
study. Venous blood from VL patients and endemic controls 
(EC) was collected in heparin. All EC were healthy household 
members of the patients.
animals
For in  vivo experiments, inbred BALB/c mice were used. For 
in  vitro experiments, mouse peritoneal macrophages (mPMs) 
were obtained from inbred mice of BALB/c strain, wild-type, and 
TLR-2 knockout mice of C57/BL6 background of either sex at 
6–10 weeks of age.
cells and culture conditions
THP-1 cells, an acute monocytic leukemia-derived human 
cell line (ATCC TIB-202TM) were maintained in RPMI-1640 
(Sigma-Aldrich, Cat. No. R8005) medium supplemented with 
10% heat-inactivated fetal bovine serum (FBS) (Gibco, Cat. No. 
10082147) and penicillin (100 U/ml), streptomycin (100 U/ml), 
and gentamycin (20 μg/ml) at 37°C in humidified air contain-
ing 5% CO2. For differentiation into macrophages, they were 
incubated with 50  ng/ml phorbol 12-myristate 13-acetate 
(PMA) (Sigma-Aldrich, Cat. No. P1585) as described previ-
ously. Human PBMCs were isolated using a Ficoll-Paque density 
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gradient (Sigma-Aldrich, Cat. No. GE-17-5442-02) from whole 
blood. Briefly, 2 ×  106 monocytes were incubated in the pres-
ence of recombinant human M-CSF (300 ng/ml) (Shenandoah 
Biotechnology Inc., Cat. No. 0114-100-03AF). Non-adherent 
cells were periodically removed followed by addition of fresh 
media containing recombinant human M-CSF (300 ng/ml) and 
10% human serum every 12 h. Cells were allowed to differentiate 
into human monocyte derived macrophages (hMDMs) for 96 h.
Mouse peritoneal macrophage monolayers were prepared as 
described previously (17). Briefly, peritoneal exudate cells were 
harvested from BALB/c or C57/BL6 mice using chilled serum-
free RPMI 1640 medium, incubated for 2 h, non-adherent cells 
were removed and the adherent cells were further incubated in 
complete RPMI 1640 medium to form macrophage monolayer.
The parasite, L. donovani (BHU1260), was derived from the 
primary culture obtained directly from the splenic aspirate of 
a human VL patient and was maintained in M-199 medium 
(Sigma-Aldrich, Cat. No. M5017) supplemented with 10% heat-
inactivated FBS at 23°C as described previously. The primary 
cultures were used only up to fourth passage and exhibited good 
infectivity in vitro.
Treatments
For siRNA transfection, THP-1 MDMs, or hMDMs were trans-
fected with gene-specific siRNAs (Bcl-2, Mcl-1, TLR-2, IL-13R) 
or scrambled negative control siRNA at a final concentration of 
25 nM. Transfection was performed using N-TERTM Nanoparticle 
siRNA Transfection System as per manufacturer’s instructions 
(Sigma Aldrich, Cat. No. N2913). Plasmid containing Bcl-2 clone 
was transfected using Lipofectamine LTX reagent with PLUS rea-
gent (Thermo Fisher Scientific, Cat. No. 15338100). During the 
entire course of study, the Bcl-2 selective small molecule inhibitor 
ABT-199 (10  nM) and in selective experiments, another Bcl-2 
inhibitor ABT-263 (10 nM) was used to inhibit Bcl-2 activity. For 
inhibition of specific cell signaling pathways, pharmacological 
small molecule inhibitors of various signaling molecules were 
added 30 min prior to the start of the experiments. The inhibi-
tors used were: 1, 4-diamino-2,3-dicyano-1,4-bis (o-aminophe-
nylmercapto) butadiene monoethanolate (U0126) (2 μM) (Sigma 
Aldrich, Cat. No. U120) and 2-(2-Amino-3-methoxyphenyl)-
4H-1-benzopyran-4-one (PD98059) (10  μM) (Sigma Aldrich, 
Cat. No. P215) for MEK1/2; 2-(4-Morpholinyl)-8-phenyl-1(4H)-
benzopyran-4-one hydrochloride (LY294002) (30  μM) (Sigma 
Aldrich, Cat. No. L9908) and wortmannin (100  nM) (Sigma 
Aldrich, Cat. No. W1628) for phosphatidylinositol 3-kinase 
(PI3-K); and Tyrphostin (AG490) (10  μM) (Calbiochem, Cat. 
No. 658401) for STAT-3.
Determination of intracellular  
Parasite Burden
Late stationary phase promastigotes were used to challenge mac-
rophages at multiplicity of infection (MOI) of 10 parasites per 
macrophage. After 2 h of incubation, the unbound parasites were 
removed by gently shaking and washing the wells with incomplete 
RPMI-1640 medium three times and the infected macrophage 
monolayers were incubated in the complete medium for 12 or 
24  h. To estimate the intracellular parasitic burden, cells were 
fixed in 4% paraformaldehyde (PFA) followed by staining with 
the DNA fluorescent probe DRAQ5 (5 μM) (Thermo Fisher, Cat. 
No. 62251) for 10 min. After washing three times with sterile PBS 
to remove the excess stain, cells were mounted in Vectashield anti-
fade mounting medium (Vector Laboratories, Inc., Burlingame, 
CA, USA) and were used to acquire images using Leica TCS SP5 
II (Leica Microsystems, Wetzlar, Germany) confocal microscope 
at 633 nm. Infecting the cells at the mentioned MOI resulted in 
a situation where 98–99% cells were infected with at least one 
parasite. At least 200 cells observed from a minimum of 15 ran-
domly selected fields were counted manually for each condition 
to determine the average number of parasites per macrophage. 
Similarly, for estimating parasite uptake, a 2-h infection period 
was used after which cells were processed, stained with DRAQ5, 
and average parasite counts per macrophage were made. The 
parasite counting was performed by a person in the laboratory 
blinded for the experimental conditions, other than the person 
performing the experiment.
immunohistochemistry
Cells fixed with 2% PFA were permeabilized with 0.1% Triton 
X-100 and incubated overnight with primary antibody against 
Bcl-2 (1:200) (Millipore, Cat. No. 05-729) or TLR-2 (1:250) 
(Novus Biologicals, Cat. No. NBP1-77843) at 4°C. Secondary 
antibody conjugated to Alexa 488 (1:400) (Invitrogen, Cat. No. 
A11001) was used to detect staining at excitation/emission 
wavelength: 490/525  nm. DNA staining was performed using 
DAPI (10 μg/ml) (excitation/emission wavelength: 647/681 nm) 
(Thermo Fisher, Cat. No. 62251). Images were captured using 
Leica TCS SP5 II (Leica Microsystems, Wetzlar, Germany) confo-
cal microscope and analyzed using an integrated Leica LAS AF 
software program.
Protein extraction and Western Blots
Cells were lysed in cell lysis buffer as described earlier (18). Cell 
lysates (30–80  μg) electrophoresed on 12% SDS polyacryla-
mide gels were transferred onto nitrocellulose membranes. 
Membrane blocking was performed in 5% fat free milk (Santa 
Cruz Biotechnology, Cat. No. sc-2325) followed by incubation 
with any of the primary antibodies like, Bcl-2 (1:1000) (BD 
Biosciences, Cat. No. 51-6511GR), Bcl-xL (1:1000) (Cell Signaling 
Technologies, Cat. No. 54H6), Mcl-1 (1:1000) (BD Biosciences, 
Cat. No. 559027), Bad (1:1000) (Santa Cruz Biotechnology, Cat. 
No. sc-492), p-Bad (1:1000) (Santa Cruz Biotechnology, Cat. 
No. sc-271963), TLR-2 (1:1000) (Novus Biologicals, Cat. No. 
NBP1-77843), pERK-1/2 (1:1000) (Cell Signaling Technologies, 
Cat. No. 9101), p-STAT-3 (1:1000) (Cell Signaling Technologies, 
Cat. No. D3A7), p-PI3K (1:1000) (Cell Signaling Technologies, 
Cat. No. 4428), p-Akt (1:1000) (Cell Signaling Technologies, Cat. 
No. 9271), iNOS (1:1000) (Santa Cruz Biotechnology, Cat. No. 
sc-8310), and β-tubulin (1:4000) (Thermo, Cat. No. RB-9249-P1). 
Subsequently, post wash, blots were incubated with correspond-
ing secondary antibodies conjugated to horseradish peroxidase. 
Protein bands were observed on X-ray film using femtoLU-
CENT™ PLUS-HRP reagent (G-biosciences, Cat. No. 786-003). 
To monitor for equal loading of proteins in each well, Western 
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blotting using antibody against β-tubulin was performed for each 
experiment.
Measurement of nitrite Production
The concentration of nitrite, the stable end product of NO, in 
culture supernatants or serum was determined by Griess’ reac-
tion as described by Biswas et al. with slight modifications (19). 
Briefly, 106 cells were plated in the wells of a 12-well culture 
plate, and after the completion of the experiments the cell-free 
supernatant from individual wells were collected and stored until 
use. About 100 μl of the sera or culture supernatants were incu-
bated with equal volume of Griess’ reagent for 20 min at room 
temp. Spectrophotometric readings were taken at 540  nm in a 
microplate reader (μQuant, BioTek Instruments Inc., VT, USA). 
Nitrite content was quantified by extrapolation from a sodium 
nitrite standard curve for each experiment.
enzyme-linked immunosorbent  
assay for il-13
IL-13-specific enzyme-linked immunosorbent assay (ELISA) 
was performed to detect level of secreted IL-13 in the cell-free 
supernatant obtained from different in vitro/ex vivo experiments 
or serum of mice using human/mouse-specific IL-13 ELISA 
kits (e-Biosciences, Cat. Nos. 88-7439-22, human; 88-7137-22, 
mouse) as per manufacturer’s instructions.
In Vivo infection experiments
Inbred BALB/c mice were grouped as untreated non-infected 
control, infected, infected vehicle control, and infected 
drug treated. Mice in last three groups were inoculated with 
Leishmania promastigotes through intra-cardiac injection with 
50 μl bolus containing 1 × 107 parasites on day 0 of the study. 
Drug (ABT-199, ABT-263 both at 15  mg/kg body weight) or 
vehicle (DMSO) was injected through tail vein. In the drug or 
vehicle control groups, injections were given for first 3  weeks, 
once every week. Mice were humanely euthanized after 5 weeks 
and spleens were dissected out, weighed, and impression smears 
were made. Parasite burden was estimated by counting splenic 
smears prepared after euthanasia. Blood was collected from mice 
and plasma was extracted for detection of nitrite and IL-13 levels 
in circulation.
statistical analysis
Standard one-way analysis of variance (ANOVA) followed 
by Bonferroni’s multiple comparison test was performed to 
derive the statistical significance between the test groups while 
comparing densitometric data of Western blots. For comparing 
nitrite concentration, parasitic burden, and mice data between 
different test groups, where information about a Gaussian 
distribution could not be conclusively derived, Mann–Whitney 
test was performed. Wilcoxon signed-rank test was applied to 
analyze the data from the paired samples. The statistical analysis 
was performed using GraphPad Prism, version 5.01 (GraphPad, 
San Diego, CA, USA). P-value of less than 0.05 was considered 
significant. The error bars of the values represent ± SEM from 
the replicates.
resUlTs
expression of Bcl-2 Family Proteins 
changes in response to Leishmania 
infection
For investigating the changes in the expression of Bcl-2 family pro-
teins after infection with L. donovani parasite, THP-1 monocyte-
derived macrophages (THP-1 MDM) were challenged at MOI of 1 
macrophage:10 parasites (Figure S1A in Supplementary Material) 
in vitro, and the levels of Bcl-2 family proteins were measured. 
A time-dependent increase in Bcl-2 was observed post infection 
(Figure 1A). The increase in Bcl-2 dominated from 2–12 h follow-
ing which there was a gradual decline. Mcl-1 protein expression 
also increased following infection and the elevated levels were 
sustained. Bcl-xL levels did not change significantly during the 
course of infection (Figure 1A). Likewise, when primary human 
macrophages derived from blood monocytes, i.e., hMDMs 
were infected with the parasites (Figure S1A in Supplementary 
Material), similar changes were observed. Both Bcl-2 and Mcl-1 
levels increased with almost identical pattern and kinetics as that 
of THP-1 MDMs (Figure 1A). An investigation into intracellular 
Bcl-2 immunostaining demonstrated predominantly perinuclear 
localization of the protein in THP-1 MDM (Figure 1B).
Concomitant increase in the levels of the antiapoptotic proteins 
Bcl-2 and Mcl-1 and decrease in the level of the pro-apoptotic 
protein Bad implied enhanced survival of the parasite-infected 
macrophages. Infected cells by default experience higher levels of 
cellular stress and therefore are at much higher risks of undergo-
ing apoptosis. Increasing expression of antiapoptotic proteins or 
reducing expression of pro-apoptotic proteins of the host cells 
are among well-documented pro-pathogenic strategies and can 
be critically effective during establishment of infection (1). To 
explore if increased Bcl-2 and Mcl-1 served any pro-parasitic 
intent by imparting higher survival advantage to the infected 
cells, macrophages were knocked down for Bcl-2 or Mcl-1 
(Figure 1C), and cell viability was checked at different time points 
post infection. Macrophages knocked down for either Bcl-2 or 
Mcl-1 showed no significant impact on viability upto 48  h of 
infection (Figure S1B in Supplementary Material). However, 
Bcl-2 knocked down macrophages showed increased cell death 
as compared with control cells at 72 h post-infection. Similar to 
Bcl-2 downregulated cells, Mcl-1 knocked down macrophages 
showed reduced viability at 72 h, however to a lesser extent (Figure 
S1B in Supplementary Material). To look for any potential impact 
on parasite internalization introduced due to knocking down of 
Bcl-2/Mcl-1, macrophages in different groups were infected for 
2 h and average parasite numbers were counted. No significant 
differences in the average number of internalized parasites were 
found among different groups, negating any possible effect of 
Bcl-2/Mcl-1 knock down on parasite uptake (Figure 1D). To look 
for possible role of Bcl-2 and Mcl-1 in the sustenance of the parasite 
inside macrophages, parasite burden was estimated under Bcl-2/
Mcl-1 knock-down conditions at 12 h of infection. Cells treated 
with Bcl-2 siRNA showed a pronounced reduction in the number 
of parasites/cell as compared to the scrambled siRNA control. 
However, unlike Bcl-2 knocked down cells, Mcl-1 knocked down 
FigUre 1 | expression of Bcl-2 and Mcl-1 increases during L. donovani infection. 
(Continued)
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macrophages did not show any significant reduction in parasite 
number (Figure 1D). To further look if this effect was specific 
to Bcl-2, Bcl-2 overexpression (Figure  1C) was carried out in 
Bcl-2 lowered cells before they were challenged with parasites. 
Bcl-2 overexpressing macrophages showed parasite burden 
comparable to control cells (Figure  1D). These observations 
suggested that elevated presence of Bcl-2 but not Mcl-1 favored 
parasite survival. The siRNA-mediated downregulation of Bcl-2 
in hMDM also resulted in lesser infection rates as compared to 
scrambled siRNA-treated cells (Figure  1D). Consequently, to 
reaffirm the role of Bcl-2 and further establish its functional 
relevance, we used Bcl-2 inhibitors ABT-199 and ABT-263 to 
block Bcl-2 function through binding site interference. Parasite 
challenge during ABT-199 or ABT-263 mediated inhibition of 
Bcl-2 in both THP-1 MDM and hMDM showed lower infection 
as compared to vehicle-treated controls (Figure  1D, ABT-199, 
ABT-263). Having obtained positive correlation between Bcl-2 
expression and parasite burden in human macrophages, we 
considered it relevant to check this hypothesis in an animal 
model. Before moving onto a mouse model, which is one of the 
two established animal models for VL, it was important to look 
at the status of Bcl-2 family proteins in mouse macrophages. 
Infection experiments with mPMs reflected similar alterations 
in the profile of Bcl-2 family proteins in  vitro, albeit, with a 
slightly different time kinetics. Here, the Bcl-2 increase peaked 
at 8 h followed by a decline and Mcl-1 showed an increase from 
8–16 h with Bcl-xL showing no noteworthy change (Figure 1E). 
Similar to human macrophages, mPMs with Bcl-2 knock down 
or in the presence of Bcl-2 functional inhibitors did not show 
reduced parasite uptake, but demonstrated lower parasite burden 
(Figure  1E). Among the pro-apoptotic members of the Bcl-2 
family, only Bad protein showed significantly altered expression. 
There was a gradual decline in Bad levels pertaining to its rapid 
phosphorylation post infection (Figure 1F). Taken together, the 
above data clearly provided evidence for a supportive role of Bcl-2 
to parasite survival within the host cells.
Bcl-2 levels influence generation  
of nO in Macrophages
Leishmania parasites are sensitive to macrophage generated NO 
(13). Prior reports in other systems attribute NO regulation to 
Bcl-2 (16). With this background, we hypothesized an inhibitory 
FigUre 1 | continued  
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(a) Bcl-2, Mcl-1, and Bcl-xL protein levels in extracts of THP-1 MDM and hMDM infected with L. donovani parasites in vitro. Note the increase in Bcl-2 from 2 h 
onward. Blots are representative of three experiments. Densitometric plots are shown below. Data are mean ± SD (n = 3). (B) Immunocytochemical staining of 
infected THP-1 MDM using anti-Bcl-2 antibody at different time points post-infection. Note increased Bcl-2 expression at 8 h showing predominantly perinuclear 
distribution as indicated by white arrows. N = nucleus. (c) Blots showing siRNA mediated downregulation of Bcl-2 and Mcl-1 in THP-1 MDM and hMDM. Control is 
without any siRNA. Scr, scrambled siRNA; KD, knockdown. Also shown is overexpression of Bcl-2 in THP-1 MDM and hMDM. OE, overexpression. Control is only 
plasmid, OE, overexpression. Blots are representative of three experiments. The blot below shows control Bcl-2 levels during treatment with only vehicle (DMSO) or 
ABT-199 or ABT-263. Bcl-2 levels remained unaffected upon these treatments. (D) Plots show parasite uptake and parasite burden during various conditions. 
Average parasite counts per macrophage have been put on the y-axis. A minimum of 200 cells was counted. Data are mean ± SEM (n = 3); ***P ≤ 0.001; 
Mann–Whitney test. Parasite uptake remained unaltered. Note significant reduction of parasite burden in siRNA or ABT-199-treated Bcl-2 downregulated cells. (e) 
Western blots of lysates of infected mPM stained for Bcl-xL, Bcl-2, and Mcl-1 showing increased expression for Bcl-2 which peaks at 8 h post-infection. Blots are 
representative of three experiments. Shown below are the densitometric plots. Data are mean ± SD (n = 3). Alongside are blots showing siRNA0-mediated 
downregulation of Bcl-2 and Mcl-1 in mPMs. Control is without any siRNA. Scr, scrambled siRNA; KD, knockdown. Shown below are bar graphs expressing 
parasite uptake and parasite burden during various treatments. Note significantly reduced parasite burden in Bcl-2 KD and ABT-199/ABT-263-treated macrophages. 
A minimum of 200 cells was counted. Data are mean ± SEM (n = 3); *P ≤ 0.05; Mann–Whitney test. (F) Western blots from THP-1 MDM and hMDM showing 
time-dependent degradation of Bad protein during infection. Bad protein undergoes degradation post phosphorylation. The blot below shows Bad phosphorylation 
upon infection. Blots are representative of three experiments.
FigUre 1 | continued
FigUre 2 | Bcl-2 increase contributes to inOs suppression. 
(Continued)
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role of excess Bcl-2 on NO production, as Bcl-2 knock down 
or its functional inhibition resulted in lower parasite burden 
(Figures 1D,E). Treatment with ABT-199 or the vehicle used for 
this inhibitor, DMSO did not have any effects on iNOS expres-
sion (Figure 2A). Infection of THP-1 MDMs resulted in a very 
low level induction of iNOS enzyme, which was also reflected in 
FigUre 2 | continued
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nitrite levels (Figures 2A,B). To look for a role of Bcl-2 protein 
in NO production during L. donovani infection, either Bcl-2 
expression was downregulated using gene-specific siRNAs or 
Bcl-2 protein function was inhibited using ABT-199/ABT-263. 
A siRNA-mediated downregulation of Bcl-2, but not Mcl-1, 
resulted into a significant increase in iNOS levels (Figure 2C). 
Similarly, functional inhibition of Bcl-2 by ABT-199 or ABT-263 
led to a significant induction of iNOS post infection (Figure 2D). 
Such interference with Bcl-2 expression or function also resulted 
in significantly higher nitrite production (Figures 2C,D), indi-
cating higher iNOS activity. These data clearly demonstrated 
a negative effect of Bcl-2 on the NO generating machinery. 
Since higher iNOS level generally corresponds to increased NO 
production, to further confirm if increased iNOS expression, 
and consequently higher NO production was responsible for 
parasite killing in the presence of Bcl-2 inhibitors, cells were 
treated with an iNOS inhibitor, LNMA. Both NO production 
as well as parasite killing was abrogated upon iNOS inhibition 
(Figures 2E–G). Bcl-2 inhibition through ABT-199 or ABT-263 
increased NO levels, but in the presence of LNMA this increase 
was not observed (Figure 2E). When parasite burden was esti-
mated, a lower parasite burden was observed with both ABT-263 
and ABT-199 treatment but this protection was significantly 
lost in the presence of LNMA (Figures  2F,G). Similar results 
were obtained with hMDMs (Figure 2H); the primary human 
macrophages demonstrated increased iNOS expression and 
nitrite levels on downregulation of Bcl-2 but not when Mcl-1 was 
lowered (Figure 2H).
To see if the parasite clearance seen upon Bcl-2 manipulation 
corresponded with NO levels in mPMs as observed in case of 
human macrophages, NO levels were quantified both during 
Bcl-2 downregulation and in the presence of Bcl-2 inhibitors 
(Figure  2I). Macrophages knocked down for Bcl-2 or treated 
with Bcl-2 inhibitors produced significantly more NO as com-
pared to control cells. Both, NO production as well as increased 
parasite clearance achieved was abrogated upon iNOS inhibition 
(Figure 2I).
Collectively, the data from both human and mouse mac-
rophages showed that parasite influenced NO production by 
modulating Bcl-2 expression. Functional inhibition of Bcl-2 
FigUre 2 | continued  
(a) Western blot showing iNOS levels during control treatments and upon infection for 24 h. (B) iNOS levels at 12 and 24 h post infection. LPS has been taken as a 
positive control. (c) Blot showing higher iNOS expression at 12 h post-infection during Bcl-2 downregulation by siRNA to Bcl-2. Note no significant change after 
inhibition with siRNA to Mcl-1. Ld, Leishmania donovani; KD, knockdown; Scr, scrambled siRNA. (D) Western blot of THP1-MDM extracts at 12 h post-infection, 
showing higher levels of iNOS when Bcl-2 protein was inhibited by ABT-199/ABT-263. The bar graphs below the western blots in (a–D) show nitrite levels in soups 
obtained from corresponding experiments. Note the correspondence between iNOS expression and the nitrite levels in all the above experiments. (e) Nitrite 
concentrations at 12 h after treatment with Bcl-2 inhibitor ABT-199 and LNMA, iNOS inhibitor. Data are mean ± SEM (n = 3). *P ≤ 0.05; Mann–Whitney test. (F) 
Parasite burden 12 h postinfection in THP-1 MDM in the presence of Bcl-2 inhibitor ABT-199 and iNOS inhibitor, LNMA. Data are mean ± SEM (n = 3). ***P ≤ 0.001; 
Mann–Whitney test. (g) Photomicrograph of infected THP-1 MDM treated with LNMA and ABT-199. Note the loss of ABT-199-conferred reduction in parasite 
burden upon inhibition of iNOS activity by LNMA. The yellow arrows indicate intracellular parasites. (h) Representative Western blots from the lysates of hMDMs 
showing increased iNOS expression at 12 h upon Bcl-2 KD and in the presence of Bcl-2 inhibitors ABT-199/ABT-263. The bar graphs below represent 
corresponding nitrite levels. Ld, Leishmania donovani; KD, knockdown; Scr, scrambled siRNA. Data are mean ± SEM (n = 3). *P ≤ 0.05; Mann–Whitney test. (i) First 
three bar graphs show nitrite concentrations at 12 h after parasite infection of mPMs upon Bcl-2, Mcl-1 KD or treatments with Bcl-2 inhibitors, ABT-199/ABT-263 
and upon inhibition of iNOS activity using LNMA treatment. The fourth bar graph shows increased parasite burden in LNMA-treated mPMs even in the presence of 
ABT-199. Ld, Leishmania donovani; KD, knockdown; Scr, scrambled siRNA; mPM, mouse peritoneal macrophage. Data are mean ± SEM (n = 3). *P ≤ 0.05, 
**P ≤ 0.01; Mann–Whitney test.
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protein augmented parasite killing owing to increased NO 
production.
Tlr-2 is required for Bcl-2 increase
Prior data suggest that Leishmania binds to macrophage surface 
through TLR-2 mediated by parasite surface lipophosphoglycans 
(20). TLR-2 is a pattern recognition receptor whose expression 
is reported to change during infection (21). A time-dependent 
upregulation of TLR-2 in THP-1 MDM post infection was 
observed (Figure  3A). This was confirmed by immunocyto-
chemical staining for TLR-2 showing elevated immunoreactivity 
(Figure  3A). Based on prior knowledge of Bcl-2 regulation by 
TLR-2 in certain cell types, we explored the status of Bcl-2 under 
conditions of downregulated TLR-2. Significantly lesser induc-
tion of Bcl-2 was observed when TLR-2 was downregulated by 
siRNA transfection prior to infection (Figure 3A). As Leishmania 
parasite physically interacts with TLR-2 on the macrophage 
surface, downregulating TLR-2 expression may affect parasite 
FigUre 3 | Tlr-2 expression increases upon infection. (a) Western blot shows a time-dependent increase in TLR-2 expression by THP-1 MDMs after 
infection with L. donovani parasite. The blots below show siRNA-mediated KD of TLR-2 and reduced induction of Bcl-2 protein in TLR-2 KD macrophages. Blots 
are representative of three independent experiments. The bar graph alongside shows slightly reduced parasite uptake by TLR-2 KD THP-1 MDMs. Next placed are 
the immunofluorescence photomicrographs showing enhanced expression of macrophage TLR-2 receptors at 12 and 24 h post infection. (B) Blot shows increased 
TLR-2 expression by hMDMs upon L. donovani infection. The blot below shows infection-induced Bcl-2 expression was diminished in TLR-2 KD hMDMs. Ld, 
Leishmania donovani; KD, knockdown; Scr, scrambled siRNA. Blots are representative of three independent experiments. The adjacent bar graph shows a 
significant reduction in the parasite uptake by TLR-2 KD hMDMs. A minimum of 200 cells were counted. Data are mean ± SEM (n = 3). *P ≤ 0.05; Mann–Whitney 
test. (c) Blot shows a time-dependent increase in TLR-2 protein in mPM post infection. Unlike peritoneal macrophages from WT animals, no significant increase in 
the expression of Bcl-2 protein was observed in TLR-2 KO mPMs in response to infection. Blots in this figure are representative of at least 3–4 experiments. The 
adjacent bar graph shows that mPMs obtained from TLR-2 KO mice show significantly lesser uptake of parasites as compared to macrophages obtained from WT 
animals. The parasite uptake was measured by counting average number of internalized parasites per macrophage 3 h postinfection. WT, wild type; KO, knockout. 
Data are mean ± SEM (n = 3); *P ≤ 0.05; Mann–Whitney test.
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internalization. To check if parasite uptake was affected in TLR-2 
downregulated cells, unbound parasites were washed after 2 h of 
infection and a count of internalized parasites showed a minor 
reduction in the parasite uptake in TLR-2 siRNA-treated cells 
(Figure 3A). Despite being statistically insignificant, this minor 
reduction in the parasite uptake was consistently observed in 
multiple experiments. Similar to THP-1 MDM, hMDM showed 
an increase in TLR-2 expression post infection (Figure 3B), and 
TLR-2 downregulation prior to infection (Figure 3B) prevented 
the increase in Bcl-2 levels (Figure  3B). Unlike THP-1 MDM, 
statistically significant reduction in the parasite uptake in TLR-2 
downregulated group was observed (P =  0.0161) (Figure  3B). 
The above observations were verified in cells from TLR-2 knock-
out mice. Wild-type mPM showed a gradual increase in TLR-2 
expression post infection (Figure 3C) with an increase in Bcl-2 
levels (Figure 3C). On the contrary, the peritoneal macrophages 
isolated from TLR-2 knockout mice of the same strain showed 
no significant increase in Bcl-2 levels post infection (Figure 3C). 
The mPMs derived from TLR-2 knockout mice also showed 
significantly reduced parasite uptake verifying that Leishmania 
11
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parasites engaged TLR-2 for entry into cells (Figure 3C). Taken 
together, the data indicate involvement of TLR-2 in the regulation 
of Bcl-2 expression and also suggest a possible role of TLR-2 in 
parasite internalization.
erK Pathway Triggered in response  
to Leishmania infection controls  
Bcl-2 levels
Searching for downstream effectors of TLR-2, changes in pPI3K, 
pAkt, and pERK1/2 were determined. Parasite challenge caused 
a time-dependent increase in phosphorylation of PI3K, Akt, and 
ERK1/2 (Figure  4A). Therefore, to determine the relationship 
between pPI3K, pAkt, pERK1/2, and Bcl-2 induction during 
infection, specific pharmacological inhibitors were used to block 
the kinase activities of the proteins leading to phosphorylation of 
PI3K, Akt, and ERK1/2. Inhibition of ERK 1/2 phosphorylation 
with U0126 resulted in an observable reduction in the infection-
induced Bcl-2 increase (Figure 4B). Both PD98059 and U0126, 
MAPK/ERK kinase inhibitors significantly prevented Bcl-2 
induction (Figure 4B) suggesting regulation of Bcl-2 through the 
MEK/ERK pathway. The inability of wortmannin and LY294002, 
the PI3K inhibitors to prevent the increase in Bcl-2 post infection 
(Figure 4B) ruled out the involvement of the PI3K pathway in 
Bcl-2 changes. NO levels were found to be significantly increased 
in the presence of ERK inhibitors U0126 and PD98059 during 
parasite invasion (Figure  4C) suggesting higher iNOS activity, 
whereas, in the presence of wortmannin and LY294002, nitrite lev-
els remained at par with only parasite-infected cells (Figure 4C). 
In consonance with the above data, presence of both U0126 and 
PD98059 showed reduced infection (Figure  4D) suggesting 
higher NO levels to be effective against the parasite, whereas, the 
presence of wortmannin did not interfere with parasite burden 
(Figure  4C). The hMDMs also produced significantly higher 
NO in the presence of ERK inhibitors (Figure 4E) and showed 
significantly reduced parasite burden (Figure 4F). In summary, 
this part of the data showed participation of MEK/ERK signaling 
pathway in L. donovani-induced increases in Bcl-2 levels, lower-
ing of NO production and higher infection rates. Clearly, MEK/
ERK acted as the downstream effectors of TLR-2 after infection 
with the L. donovani parasite leading to Bcl-2 increase favoring 
parasite survival.
il-13 regulates Bcl-2 through sTaT-3
Modulation of cytokines is an important event during infection. 
From our in  vitro studies, it was observed that challenge with 
L. donovani parasite caused a time-dependent increase in IL-13 
levels (Figure  5A). A report involving patient data has shown 
increased level of IL-13 in the VL sera (22) that has been also 
confirmed in our study with human VL subjects (unpublished 
data). Therefore, our in vitro observations were similar to the pre-
viously reported patient data. IL-13 is responsible for inducing a 
host of different functions on different kind of cell types including 
macrophages (23). As it is known that Bcl-2 levels are regulated by 
IL-13 via STAT-3 in certain cell types (24), we sought to explore 
if Bcl-2 was responding to IL-13 signals. THP-1 MDMs were 
exposed to recombinant IL-13 (rIL-13) and a time-dependent 
increase in Bcl-2 levels and increase in the phosphorylation of 
STAT-3 was recorded (Figure  5B). STAT-3 phosphorylation is 
a downstream event of IL-13 exposure, as is known in other cell 
types of the immune lineage. To further establish the role of IL-13 
in Bcl-2 induction, IL-13 signaling was perturbed at different lev-
els: at the levels of IL-13 receptor (IL-13R) and JAK-2, which is the 
upstream kinase responsible for phosphorylating STAT-3. THP-1 
MDMs with IL-13R downregulation using siRNAs to IL-13R or 
pretreated with AG490, an inhibitor of JAK-2 displayed reduced 
phosphorylation of STAT-3 (Figure  5C) upon treatment with 
rIL-13. These conditions also prevented Bcl-2 increases during 
exposure to rIL-13 (Figure 5C). Importantly, infection-induced 
STAT-3 phosphorylation and Bcl-2 increase declined when 
cells were challenged with parasites in IL-13R downregulated 
conditions or in the presence of AG490 (Figure 5D). Reduced 
phosphorylation of STAT-3 was also observed in the presence of 
PD98059, an ERK inhibitor (Figure 5D), indicating an involve-
ment of pERK 1/2 in STAT-3 phosphorylation in addition to 
IL-13-JAK-2 axis during infection. This finding also suggested 
convergence of TLR-2-ERK and IL-13-JAK-2 axes at the level of 
STAT-3. In all, the data suggested that infection-induced induc-
tion of Bcl-2 was predominantly mediated through STAT-3.
Infection of hMDMs with L. donovani parasites generated 
a similar response like that of THP-1 MDMs by inducing a 
time-dependent increase in IL-13 (Figure  5E). The rIL-13 
administration to naive hMDMs induced a Bcl-2 increase similar 
to THP-1 MDMs (Figure  5E). Under IL-13R downregulated 
conditions, both rIL-13 and the Leishmania parasites were unable 
to induce significant STAT-3 phosphorylation and Bcl-2 increase 
(Figure  5E) in hMDMs. In summary, in both THP-1 MDMs 
and hMDMs, IL-13 contributed to Bcl-2 induction via STAT-3 
phosphorylation.
In Vivo inhibition of Bcl-2 abrogates 
infection
It was important to test the occurrence and relevance of the 
in  vitro findings in an animal model of VL. To test the hypo-
thetical role of Bcl-2 inhibition on the disease outcome in vivo, 
L. donovani infection was established in BALB/c mice and the 
role of Bcl-2 small molecule inhibitors, ABT-199 and ABT-263, 
was investigated. It should be noted that the inoculums used to 
infect mice were derived directly from the primary cultures of the 
parasites in the splenic aspirate of a VL patient. Splenomegaly is 
a common feature of VL where the size of the spleen is in general 
an indication of the parasitic burden and, therefore, the active 
disease. Mice treated with the Bcl-2 small molecule inhibitors 
showed significantly lesser spleen size and weight as compared to 
that from mice without the inhibitor treatments (Figure 6A). In 
support of the above data, the number of infected macrophages 
per spleen was observed to be significantly higher in control 
and only vehicle-treated groups as compared to ABT-199- and 
ABT-263-treated animals (Figure  6A), suggesting reduction in 
the number of infected macrophages in low Bcl-2 conditions. The 
in vitro observation of increased cellular NO production when 
Bcl-2 was inhibited was confirmed in vivo where ABT-199- and 
ABT-263-treated mice showed significantly higher serum nitrite 
FigUre 4 | MeK-MaPK/erK but not Pi3K-akt activation regulates Bcl-2 increase in ThP-1 MDM. (a) Representative Western blots for pPI3K, pAkt, and 
pERK upon infection with L. donovani. PI3K is phosphorylated during early infection within 30–60 min. Note pretreatment with wortmannin, which is an inhibitor of 
PI3K phosphorylation, completely abrogates Akt phosphorylation. mpi, minutes post infection. (B) Blots showing effect of PI3K and ERK inhibitors on Bcl-2 
induction during infection. The first blot shows significant decrease of infection-induced Bcl-2 on inhibition of ERK phosphorylation with U0126 and PD98059 
(MEK1/2 inhibitors). The second blot in the figure shows no significant difference in the expression of Bcl-2 protein in the presence of PI3K inhibitors, wortmannin 
and LY294002 at 12 h postinfection. The third blot shows stabilization of the Bad protein in the presence of PI3K inhibitors showing PI3K mediated degradation of 
Bad protein during infection. Ld, Leishmania donovani; Veh, vehicle (DMSO). The blots in this figure are representative of three independent experiments. (c) Nitrite 
concentration measurements 12 h post infection in the presence of ERK or PI3K inhibitors. (D) Parasite burden in the presence of ERK or PI3K inhibitors. Note 
reduced parasite burden in the presence of ERK inhibitors. (e,F) show nitrite measurements and parasite burden respectively for hMDMs in the presence of ERK/
PI3K inhibitors. A minimum of 200 cells was counted for estimating parasite burden. Data are mean ± SEM (n = 3); *P ≤ 0.05; Mann–Whitney test.
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FigUre 5 | il-13 regulates Bcl-2 expression through sTaT-3 activation. (a) A time-dependent increase in IL-13 secretion post infection in vitro. Data are 
mean ± SEM (n = 3), **P < 0.01, Mann–Whitney test. Western blot shown below demonstrates early phosphorylation of STAT-3 in response to infection. mpi, 
minutes post infection. (B) Blots showing increase in Bcl-2 expression and STAT-3 phosphorylation at different time points in vitro upon treatment with rIL-13 (1 ng/
ml). (c) Western blot showing siRNA mediated downregulation of IL-13 receptors. Blots shown below demonstrate a reduction in STAT-3 phosphorylation in IL-13R 
downregulated cells or in the presence of AG490, a JAK2 inhibitor. Blot further below shows a significant decrease in rIL-13-induced Bcl-2 expression both in 
IL-13R knockdown cells as well as in cells treated with AG490. Cont, no treatment. Scr, scrambled siRNA; KD, knockdown; rIL-13, recombinant IL-13. (D) Blots 
show reduced phosphorylation of STAT-3 when expression of IL-13R was reduced (as compared to scrambled siRNA treated cells) as well as after pretreatment 
with AG490 at 90 min post infection. Blots below show Bcl-2 levels in infected cells with downregulated IL-13R or JAK-2 inhibition. Blot immediately below shows 
reduction in phosphorylated STAT-3 upon PD98059 treatment. LD, Leishmania donovani. Cont, no infection; Veh, vehicle (DMSO). Blots are representative of at 
least three experiments. (e) hMDMs show a time-dependent increase in secretion of IL-13 upon infection in vitro. Western blot immediately below shows increase in 
Bcl-2 expression upon treatment with rIL-13 (1 ng/ml). Blot below shows IL-13 receptor downregulation upon IL-13 receptor siRNA treatment. Blots further below 
show that both rIL-13/infection-induced STAT-3 phosphorylation as well as Bcl-2 induction are significantly reduced upon IL-13R KD or JAK-2 inhibition. LD, 
Leishmania donovani; KD, knockdown; rIL-13, recombinant IL-13; IL-13R KD, IL-13 receptor knockdown.
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levels as compared to vehicle-treated controls (Figure  6B). 
Infection-induced increase in IL-13 observed in  vitro was also 
visible in the in  vivo model where serum IL-13 levels were 
consistently higher in the infected animals (Figure 6C). On the 
other hand, ABT-199- and ABT-263-treated groups showed 
significantly lesser serum IL-13 (Figure 6C). When lysates from 
mouse spleen were checked for Bcl-2 protein, infected mice from 
all groups showed elevated Bcl-2 levels as compared to the unin-
fected control (Figure 6D). ABT-199 treatment apparently had no 
effect on Bcl-2 expression in vivo. While lysates from uninfected 
control mice showed no expression of the iNOS protein, barely 
detectable iNOS levels were visualized from L. donovani-infected 
group (Figure 6D). Interestingly, higher iNOS levels were found 
in the lysates from ABT-199-treated group mice (Figure  6D), 
possibly accounting for higher nitrite levels in the sera of ABT-199 
treated. The in vivo data showing decreased parasite burden when 
infected mice were treated with Bcl-2 inhibitors clearly indicated 
an antileishmanial effect of the drugs. The confirmation of higher 
nitrite levels in vivo corroborated the data obtained at the cellular 
level suggesting NO-mediated killing of the parasites. Taken 
together, the data from in vitro experiments were reproducible 
in the animal model.
FigUre 6 | aBT-199 treatment reduces parasite burden in mice. (a) L. donovani infection-induced splenomegaly in mice (b) which shows significant reduction 
in ABT-199 (d) and ABT-263 (e) treated group. Scatter plots show spleen weight and splenic parasite burden in terms of Donovan units. Note the reduction in total 
splenic weight as well as parasite burden in ABT-199- and ABT-263-treated group. LDU, Leishman Donovan units; Ld, Leishmania donovani; Veh, vehicle (DMSO). 
(B) Griess’ assay shows a significant increase in the serum nitrite levels in ABT-199 as well as ABT-263 treated mice as compared to only infection or vehicle treated 
controls, with negligible concentrations of serum nitrite. (c) IL-13 ELISA shows elevated levels of IL-13 cytokine in the serum of mice infected with L. donovani. Note 
that ABT-199- and ABT-263-treated mice show lower levels of IL-13. Vehicle controls show IL-13 levels comparable to only infection group. Data in (a–c) are 
mean ± SEM (n = 6–8); *P ≤ 0.05, ***P < 0.001; Mann–Whitney test. (D) Western blots from crude splenic lysates show increased Bcl-2 expression in all infected 
groups. ABT-199 treatment had no effect on the Bcl-2 expression. On the other hand ABT-199-treated group showed increased iNOS expression. Adjacent bar 
graphs show the densitometric plots for the Bcl-2 and iNOS blots respectively. Ld, Leishmania donovani; Veh, vehicle (DMSO). *P ≤ 0.05; Mann–Whitney test.
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human Vl subjects show elevated Bcl-2 
levels and Deficient inOs expression
Sera from VL patients show significantly elevated levels of IL-13 
(22), which may result into its downstream biological effects in 
the cells of monocyte lineage. Our in vitro data showed increased 
expression of Bcl-2 in response to IL-13, therefore to look at the 
status of Bcl-2 in the human subjects, PBMCs were isolated and 
Bcl-2 expression was checked in the lysates. Six out of nine VL 
patients presented with increased Bcl-2 expression as compared 
to the healthy controls (Figure 7A). Based on our in vitro data 
on human macrophages, increased Bcl-2 expression corre-
sponded to deficient NO response. Therefore, it was important 
to look at the same in the VL patients. PBMCs from VL patients 
expressed barely detectable levels of the iNOS protein, which 
was also reflected in the nitrite levels in the corresponding sera 
(Figure  7B). When paired patients samples were checked for 
iNOS, a substantial increase in the expression was observed 
posttreatment which was again reflected in the level of serum 
nitrites (Figure 7B).
DiscUssiOn
In almost every instance of a pathogenic invasion, the most 
conspicuous motive behind manipulation of the Bcl-2 family 
members is to establish a safer niche where the pathogen may 
reside and multiply itself to bring about a state of an established 
infection. In this context, even a highly virulent pathogen is con-
tinuously under the hazard of being non-selectively killed due to 
induction of apoptosis in the infected host cell. Therefore, apopto-
sis represents a very primitive and highly evolved innate immune 
mechanism and a successful pathogen may continuously need to 
be able to manipulate it. Even though a substantial amount of 
literature exists on the various signaling molecules manipulated 
by the Leishmania parasite (25), there are no reports on how the 
pro and antiapoptotic molecules of the Bcl-2 family behave in 
response to L. donovani infection. This is important from two 
points of view; first, because Bcl-2 family of proteins control a 
variety of cellular functions and therefore, the possibility of them 
being manipulated by the parasite is high and, second, Bcl-2 is 
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FigUre 7 | Bcl-2 and inOs protein levels in the human Vl subjects. (a) The western blot shows Bcl-2 expression in the PBMCs obtained from the blood of 
human VL patients. The adjacent bar graph shows densitometric average of the patient (P1-P9) Bcl-2 levels as compared to healthy controls. *P ≤ 0.05; Mann–
Whitney test. (B) Blots show iNOS protein levels in the PBMCs of VL patients (P1–P5), pre and post treatment. The adjacent plot shows densitometric comparison 
of iNOS levels pre and post treatment. The next bar graph shows nitrite measurements in the serum of the same patients, pre and post treatment. *P ≤ 0.05; 
Wilcoxon signed-rank test. (c) Schematic showing the involvement of signaling pathways during Leishmania infection.
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already an established drug target in diseases like cancer where it 
is upregulated (26, 27), and therefore, if functionally important 
could also be considered as a drug target in leishmaniasis. In this 
report, we present evidence of a novel role of Bcl-2 protein in the 
sustenance of L. donovani infection and suggest that it could be a 
molecule for evaluation as a potential drug target.
Our observations showing increased expression of Bcl-2 and 
Mcl-1 proteins during L. donovani infection are in consonance 
with reports of enhancement in the levels of antiapoptotic 
members of the Bcl-2 family during viral and bacterial infections 
like HIV-1 (28) and Mycobacterium tuberculosis (11). Unlike 
the mycobacterial system, where creating a deficiency of the 
antiapoptotic Bcl-2 proteins resulted in accelerated bacterial 
clearance due to enhanced apoptosis of the infected host cells, 
host macrophages harboring Leishmania parasites did not readily 
undergo apoptosis even in a background deficient for Bcl-2 or 
Mcl-1. However, macrophages consistently showed significantly 
reduced number of parasites under a Bcl-2-deficient background. 
The experiments showing reduction in the parasite numbers dur-
ing siRNA-mediated downregulation of host Bcl-2 but not Mcl-1 
suggested specific involvement of Bcl-2 in the parasite survival 
through mechanism/s independent of apoptosis. Although 
pathogens like Mycobacterium tuberculosis (29), Trichomonas 
vaginalis (30), Streptococcus pneumoniae (31), and hepatitis C 
virus (32) use Mcl-1 to their advantage, Mcl-1 levels in our studies 
did not appear to have significant effect on Leishmania survival 
per  se. However, Leishmania-infected macrophages knocked-
down for Mcl-1 exhibited statistically higher mortality at 72  h 
postinfection. In this context, increased Mcl-1 levels, in addition 
to Bcl-2 may also confer a survival advantage to the infected 
macrophages. Generation of microbicidal molecules, like NO or 
reactive oxygen species, by the host macrophages poses a major 
challenge to the invading parasite (33). Our results showed 
significantly increased iNOS activity during infection, when 
either Bcl-2 expression or function was inhibited, suggesting an 
inhibitory role of Bcl-2 on NO production. To our knowledge, 
this is the first report where a very close involvement of host 
Bcl-2 in infection related events other than regulation of host-
cell apoptosis has been demonstrated during a parasitic infection. 
The reversal of parasite elimination by LNMA, an iNOS inhibitor, 
even in the presence of Bcl-2 inhibitors suggested a crucial role 
of iNOS activity in parasite killing. Defective NO response after 
infection leads to resistance to antimonial drugs, which form 
the first line of therapy against leishmaniasis (34) indicating 
importance of this reactive species in the antimicrobial arsenal of 
the host cells. In addition to NO, reactive oxygen intermediates 
(ROIs) do contribute to parasite clearance (35); however, under 
these circumstances NO seems to be critical for Leishmania kill-
ing. The role of Bcl-2 in regulating microbicidal activities in the 
macrophages in response to L. donovani infection shown in this 
study is a novel observation, suggesting a potential use of Bcl-2 
manipulation for interfering with parasite survival.
Having established an important role of Bcl-2 in the regu-
lation of NO, two things became important in the purview of 
our study: to understand the mechanism/s which led to Bcl-2 
induction in the first place, and, second, how the increased 
Bcl-2 levels may affect iNOS expression or activity. To address 
the first question, we took some insight from the cancer models, 
where Bcl-2 overexpression is the etiological factor (36). Bcl-2 
induction in some of these transformed cells has been attributed 
to IL-13-mediated activation of STAT-3 (37). STAT-3 upon 
activation-induced dimerization translocates to the nucleus 
where it may bind to the Bcl-2 promoter with high affinity 
and cause robust Bcl-2 induction (37). Cytokine profiling of 
Leishmania-infected macrophages showed increased expression 
of IL-13 in the supernatant, entailing possible involvement of 
IL-13 signaling as a cause of Bcl-2 induction. Our results indeed 
supported this hypothesis where infection-induced expression 
of Bcl-2 was shown to be majorly regulated by the IL-13-JAK2-
STAT-3 axis. Manipulations both at the level of IL-13R as well 
as JAK-2 resulted in significant abrogation of Bcl-2 induction. 
IL-13 is a pleiotropic cytokine produced by Th-2 cells, with 
anti-inflammatory properties having a major role in allergic 
inflammation; however, the effects of IL-13 appear to be context 
and model specific. In a mouse model, IL-13 was described as a 
susceptibility factor during L. major infection (38). An earlier 
report has shown presence of IL-13 in the sera of VL patients 
(22) but it is not known if this cytokine plays any role in the 
etiology of VL. By demonstrating the role of IL-13 in the regula-
tion of Bcl-2 expression, our studies demonstrate a previously 
unexplored pro-parasitic action of this cytokine and propose a 
role for this cytokine in the pathogenesis of VL.
Toll-like receptor-2 is a pattern recognition receptor associated 
with recognition of LPG on the surface of the Leishmania parasite 
(20). Engagement of TLR-2 may lead to activation of myriads of 
signaling cascades, including PI3K (39) and ERK (40). Either of 
these kinases is known to induce Bcl-2 in mammalian cells (41). 
We found activation of both of these molecules at early stages 
during infection; however, only the latter was found to mediate 
Leishmania-induced Bcl-2 expression. Interestingly, inhibition of 
ERK phosphorylation also resulted in partial inhibition of STAT-3 
activation, showing convergence of IL-13-JAK-2 and TLR-2-ERK 
pathways at the level of STAT-3 to regulate Bcl-2 expression. The 
schematic presented in Figure  7C summarizes these findings. 
Our in vitro data therefore suggested role of cascades downstream 
of TLR-2 in the regulation of Bcl-2 family members during 
Leishmania infection. TLR-2 on the macrophage surface also 
appeared to facilitate parasite internalization, at least in primary 
macrophages. These results suggest a defining role of the early 
interaction between the parasite and the TLR-2 molecules on the 
host-cell surface.
To establish these finding in vivo, we utilized a mouse model of 
VL. Mouse and hamster are the two established animal models of 
VL (42). Hamsters are characterized by a generalized deficiency 
in their capacity to generate NO, and to a certain extent ROIs 
(43). Not only is it easier to establish L. donovani infection in 
hamsters, they also show a relatively rapid progression to the 
state of a full blown VL phenotype. This inherent deficiency to 
mount a detectable NO response may account for such rapid 
progression of the active disease. Owing to the reason that our 
in  vitro data showed a strong implication of the NO response, 
choice of mouse as our animal model was obvious. The results 
coming from animal experiments showed good agreement with 
our in vitro data, where higher expression of Bcl-2 protein was 
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observed in the splenic tissue of infected mice and treatment with 
Bcl-2 inhibitors showed significantly reduced splenic size/weight 
as well as parasite burden. Treatment with Bcl-2 inhibitors also 
resulted into a better NO response by the infected mice. Infected 
mice consistently showed elevated levels of IL-13 in their sera, 
which dramatically reduced upon treatment with the Bcl-2 inhibi-
tors and was in close correspondence with the parasitic burden. 
These findings were in vivo validation of the earlier observations, 
on the basis of which we had hypothesized a functional role 
of infection-induced Bcl-2 in the pathogenesis of VL and had 
proposed use of Bcl-2 inhibitors as a therapeutic intervention. 
Taking this work one step further, we were able to see the actual 
Bcl-2 and NO levels in the human VL patients, where PBMCs 
from six out of nine patients presented with higher Bcl-2 expres-
sion. When iNOS protein expression was observed in the paired 
samples, a fair increase in iNOS expression was observed post 
treatment. Patients prior to treatment with antileishmanial drugs 
showed no detectable expression of the iNOS protein, indicating 
complete suppression of a functional NO response during VL. 
The differences in the serum nitrite levels were even starker as 
we observed significantly higher levels of NO in the patient sera 
post treatment.
Collectively, this study provides a strong evidence of involve-
ment of the host Bcl-2 protein in the sustenance of L. donovani 
infection and defines a novel mechanism through which host-
derived IL-13 mediates a pro-parasitic role. Diminution of infec-
tion on Bcl-2 inhibition provides an opportunity for using Bcl-2 
as an antileishmanial target.
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FigUre s1 | Leishmania donovani infection of different macrophage cell 
types. (a) Confocal photomicrographs of THP-1MDMs, hMDMs and mPMs 
infected with L. donovani at an MOI of 1 macrophage:10 parasites. The Bar 
graph shows average infection counts at MOIs of 1:10 and 1:20 respectively in 
the three aforementioned cell types in vitro/ex vivo. The infection ratios shown 
here are averages obtained from counting a minimum of 200 cells from at least 
15 randomly selected fields. (B) Plot shows % apoptosis in the THP-1 MDMs 
upon infection at different time points. The y-axis shows percentage of Annexin 
positive cells. Cells were either left untreated or were knocked down for Bcl-2 or 
Mcl-1. Cells transfected with scrambled siRNAs were taken as a control.
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